Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients

Oncology Letters

Volumn 2, Issue 4, 2011, Pages 693-699

  Chen, Qingyong ^a   Fei, Jun ^a   Wu, Lijun ^a   Jiang, Zhongyong ^a   Wu, Yuquan ^a   Zheng, Yun ^a   Lu, Guohua ^b  

^a The 117th PLA Hospital   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cathepsin B; Cathepsin L; Cysteine C; Lung cancer; Progonosis; Sera; Urokinase plasminogen activator; Urokinase plasminogen activator receptor

Indexed keywords

CATHEPSIN B; CATHEPSIN L; CYSTATIN C; UROKINASE; UROKINASE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN ANALYSIS; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS;

EID: 79958036150     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2011.302     Document Type: Article

References (23)

1. Sloane BF, Herman CJ and Padarathsingh M: Molecular mechanisms of progression and metastasis of human tumors: a pathology B study section workshop. Working Report from the Division of Research Grants, NIH. Cancer Res 54: 5241-5245, 1994.
2. Thomssen C, Schmitt M, Goretzki L, et al: Prognostic value of the cysteine proteases cathepsins B and cathepsin L in human breast cancer. Clin Cancer Res 1: 741-746, 1995.
3. Kos J, Stabuc B, Schweiger A, et al: Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3: 1815-1822, 1997.
4. Kayser K, Richter N, Hufnagl P, Kayser G, Kos J and Werle B: Expression, proliferation activity and clinical significance of cathepsin B and cathepsin L in operated lung cancer. Anticancer Res 23: 2767-2772, 2003.
5. Kos J and Lah TT: Cysteine proteinases and their endogenous inhibitors: Target proteins for prognosis, diagnosis and therapy in cancer (Review). Oncol Rep 5: 1349-1361, 1998.
6. Kos J, Werle B, Lah T and Brunner N: Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15: 84-89, 2000.
7. Krepela E, Prochazka J, Karova B, Cermak J and Roubkova H: Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma 45: 318-331, 1998.
8. Andreasen PA, Kjoller L, Christensen L and Duffy MJ: The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22, 1997.
9. Pedersen H, Grondahl-Hansen J, Francis D, et al: Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54: 120-123, 1994.
10. Pedersen H, Brunner N, Francis D, et al: Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675, 1994.
11. Kos J, Smid A, Krasovec M, et al: Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol Chem Hoppe Seyler 376: 401-405, 1995.
12. Schmitt M, Janicke F, Moniwa N, Chucholowski N, Pache L and Graeff H: Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler 373: 611-622, 1992.
13. Sukoh N, Abe S, Ogura S, et al: Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer. Cancer 74: 46-51, 1994.
14. Kos J, Nielsen HJ, Krasovec M, et al: Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res 4: 1511-1516, 1998.
15. Fujise N, Nanashim A, Taniguchi Y, et al: Prognostic impact of cathepsin B and matrix metalloproteinase-9 in pulmonary adenocarcinomas by immunohistochemical study. Lung Cancer 27: 19-26, 2000.
16. Werle B, Kraft C, Lah TT, et al: Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer 89: 2282-2291, 2000.
17. Cordes C, Bartling B, Simm A, et al: Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival. Lung Cancer 64: 79-85, 2009.
18. Cox JL, Sexton PS, Green TJ and Darmani NA: Inhibition of B16 melanoma metastasis by overexpression of the cysteine proteinase inhibitor cystatin C. Melanoma Res 9: 369-374, 1999.
19. Kos J, Krasovec M, Cimerman N, Nielsen HJ, Christensen IJ and Brunner N: Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin Cancer Res 6: 505-511, 2000.
20. Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C and Brambilla E: Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin Cancer Res 5: 2094-2102, 1999.
21. Salden M, Splinter TA, Peters HA, et al: The urokinase-type plasminogen activator system in resected non-small-cell lung cancer. Rotterdam Oncology Thoracic Study Group. Ann Oncol 11: 327-332, 2000.
22. Almasi CE, Hoyer-Hansen G, Christensen IJ and Pappot H: Prognostic significance of urokinase plasminogen activator receptor and its cleaved forms in blood from patients with non-small cell lung cancer. Acta Pathol Microbiol Immunol Scand Suppl 117: 755-761, 2009.
23. Corticchiato O, Cajot JF, Abrahamson M, Chan SJ, Keppler D and Sordat B: Cystatin C and cathepsin B in human colon carcinoma: expression by cell lines and matrix degradation. Int J Cancer 52: 645-652, 1992.